Materialise NV Earnings Call: Medical Leads, Manufacturing Lags

Materialise NV ((MTLS)) has held its Q4 earnings call. Read on for the main highlights of the call.

Materialise NV’s latest earnings call struck a cautiously upbeat tone, as stronger Q4 revenue, improved profitability and robust cash generation offset ongoing weakness in its Manufacturing segment. Management highlighted powerful momentum in the Medical and Software units, arguing that these engines, combined with a solid balance sheet, put the company on firmer footing despite macro and FX headwinds.

Revenue Growth and Margin Rebound in Q4

Consolidated Q4 revenue climbed 6.8% year on year to EUR 70.2 million, while gross profit rose to EUR 40.8 million, a 58.1% margin that underscores improved mix and cost discipline. Adjusted EBITDA more than doubled to EUR 9.5 million, lifting the margin to 13.6%, and adjusted EBIT reached EUR 4.0 million with net profit of EUR 6.2 million, more than twice last year.

Medical Division Delivers Double-Digit Expansion

Materialise Medical continued to be the company’s standout performer, posting a 16% revenue jump in Q4 to a record EUR 37 million and 15% growth for the full year to EUR 134 million. The unit generated EUR 13 million of adjusted EBITDA in Q4 with an impressive 35% margin and surpassed a historic milestone of more than 700,000 patients treated with its personalized solutions.

Software Shift Toward Recurring Cloud Revenue

Software revenue in Q4 held roughly flat at around EUR 11 million despite FX pressure, but the quality of sales improved as recurring revenue from maintenance and licenses grew 4% year on year. Recurring streams represented about 82% of software revenue in 2025 versus 74% in 2024, and adjusted EBITDA rose to EUR 1.7 million with a 15.5% margin as the cloud and subscription transition progressed.

CO‑AM Brix Drives Efficiency in Production

Management showcased CO‑AM Brix and process automation as a key technological differentiator, citing dramatic productivity gains in internal production trials. Nesting time was cut from 45 minutes to just one minute, bill processing accelerated by a factor of 20, total build time fell by roughly 15% and error rates dropped from 10% to below 0.1%, pointing to tangible value for industrial customers.

Cash Generation Underpins a Strong Balance Sheet

Materialise closed the year with EUR 134 million in cash and EUR 63.1 million in gross debt, reflecting a comfortable net cash position that provides strategic flexibility. Q4 free cash flow reached EUR 4.5 million, full‑year free cash flow topped EUR 15 million and operating cash flow exceeded EUR 25 million, while software‑related deferred revenue climbed to EUR 48.8 million within a total deferred revenue base of EUR 60.9 million.

Capital Market Moves and Buyback Program

To enhance shareholder optionality, the company completed an additional listing on Euronext Brussels under the same MTLS ticker without issuing new shares or raising capital. It also launched a share repurchase program of up to EUR 30 million and by late January had already acquired 187,500 shares, signaling management’s confidence in the long‑term value of the business.

Manufacturing Segment Remains Under Pressure

The Manufacturing segment continued to drag on results, with Q4 revenue slipping 2% to EUR 22.2 million and full‑year revenue down 13% to EUR 92.5 million amid weak prototyping demand. Adjusted EBITDA was negative EUR 2.2 million in Q4 and negative EUR 4.2 million for the year, and management cautioned that macro headwinds are likely to keep manufacturing flat to down through 2026.

Software Nonrecurring Sales and FX Weigh on Growth

While subscription and maintenance income rose, nonrecurring software revenue fell 19% in Q4, contributing to a 7% full‑year decline in software sales to EUR 41 million as the business model transitions. Unfavorable foreign exchange, particularly a weaker U.S. dollar, further pressured reported revenue and segment figures, muting some of the underlying operational progress.

One‑Off Listing Costs and Higher R&D Spend

Earnings were also affected by approximately EUR 750,000 of nonrecurring expenses tied to the new Euronext Brussels listing, temporarily inflating operating costs. Overall operating expenses increased only 1.5% for the year, with the rise largely attributable to stepped‑up R&D investment that management argues is critical for sustaining innovation while still enforcing cost controls.

Strategic Contracts and a Data Point to Clarify

Management pointed to strategic wins in aerospace and defense and a shift toward series manufacturing as important long‑term growth drivers, though they acknowledged that revenue contributions from these contracts will ramp more slowly than previously hoped. The call also featured inconsistent references to net cash levels, with different figures cited, a discrepancy investors will likely want management to clarify in future disclosures.

Guidance and Outlook Hinge on Medical and Software

For 2026, Materialise guided to revenue of EUR 273–283 million and adjusted EBIT of EUR 10–12 million, banking on sustained double‑digit growth in the Medical division and completion of the Software transition to a predominantly subscription model. Management expects Manufacturing to remain flat to down as macro pressures linger but plans to keep investing in Medical and Software while maintaining tight cost control, supported by its strong cash position, healthy cash generation and active buyback.

Materialise’s earnings call painted a picture of a company in transition, with powerful secular growth in Medical and a more predictable Software model gradually offsetting cyclical manufacturing headwinds. With margins improving, cash piling up and technology like CO‑AM Brix enhancing its competitive edge, the key question for investors will be how quickly strategic manufacturing wins convert into meaningful revenue and profit contributions.